touchNEUROLOGY caught up with Tahseen Mozaffar (University California, Irvine, CA, USA) to discuss the results from the PROPEL study (NCT03729362) investigating the use of AT-GAA for the treatment of late-onset Pompe disease.
- Could you tell us a little about late onset Pompe disease and the unmet needs in its treatment? (0:15)
- What is AT-GAA and what is its mechanism of action? (1:28)
- What clinical evidence to date supports the use of AT-GAA for the treatment of late-onset Pompe disease? (3:29)
- What are the aims and design of the PROPEL study? (7:51)
- What are the clinical endpoints of the study? (8:44)
Disclosures: Tahseen Mozaffar has served as an advisor to Amicus on trial design; and has served as an investigator on Amicus’ clinical trials on Pompe Disease.
Support: Interview and filming supported by Touch Medical Media
Share this Video
Related Videos In Neuromuscular Diseases
Francesco Saccà, EAN 2022: Improving quality of life for patients with generalized myasthenia gravis – ADAPT trial findings
The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. Questions: 1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14) […]
James Howard AAN 2022: Ravulizumab for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis – Results from the phase 3 CHAMPION-MG OLE trial
Ravulizumab has recently been approved by in the US for the treatment of adults with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). Prof. James Howard (The University of North Carolina at Chapel Hill, NC, USA) kindly joins touchNEUROLOGY to discuss the phase 3 CHAMPION-MG trial open label extension study that evaluated the efficacy and […]
James Howard, AAN 2022: Unmet needs in the treatment of myasthenia gravis
Myasthenia gravis (MG) is a rare autoimmune disorder caused by antibodies that act against the myoneural junction, resulting in weakness of the skeletal muscles. Prof. James Howard (The University of North Carolina at Chapel Hill, CA, USA) discusses the unmet needs in the treatment of this rare disease, including, quality of life of patients, response to […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!